A Combination Phase I Open Label Dose Escalation Study of Concomitant Administration of BIBW 2992 With BIBF 1120 in Patients With Advanced Solid Tumors
1. Male or female patients with confirmed diagnosis of advanced, non-resectable and/or
metastatic solid tumors, who have failed conventional treatment, or for whom no
therapy of proven efficacy exists, or who are not amenable to established forms of
2. Age 18 years or older.
3. Life expectancy of at least three (3) months.
4. Written informed consent that is consistent with ICH-GCP guidelines.
5. Eastern Cooperative Oncology Group performance score 0, 1or 2.
6. Patients recovered from any therapy-related toxicities from previous chemo-,hormone-,
immuno-, or radiotherapies to CTC <= Grade 1.
7. Patients must have recovered from previous surgery.
1. Active infectious disease.
2. Gastrointestinal disorders that may interfere with the absorption of the study drug
or chronic diarrhea.
3. Serious illness or concomitant non-oncological disease considered by the investigator
to be incompatible with the protocol.
4. Patients with untreated or symptomatic brain metastases. Patients with treated,
asymptomatic brain metastases are eligible if there has been no change in brain
disease status for at least four (4) weeks, no history of cerebral edema or bleeding
in the past four (4) weeks and no requirement for steroids or anti-epileptic therapy.
5. Cardiac left ventricular function with resting ejection fraction <50%.
6. Absolute neutrophil count (ANC) less than 1500/mm3.
7. Platelet count less than 100,000/mm3.
8. Bilirubin greater than 1.5 mg/dl (>26 ¿mol /L, SI unit equivalent).
9. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than two
and a half times the upper limit of normal (2.5 X ULN ).
10. Serum creatinine greater than 1.5 mg/dl (>132 ¿mol/L, SI unit equivalent).
11. Women and men who are sexually active and unwilling to use a medically acceptable
method of contraception.
12. Pregnancy or breast-feeding.
13. Treatment with other investigational drugs; chemotherapy, immunotherapy, radiotherapy
or hormone therapy (including LHRH agonists, megestrol acetate, or other hormones
taken for breast cancer or prostate cancer); participation in another clinical study
within the past 4 weeks before start of therapy or concomitantly with this study.
Treatment with bisphosphonates is allowed.
14. Treatment with an EGFR- or HER2 inhibiting drug within the past 4 weeks before start
of therapy or concomitantly with this study (2 weeks for trastuzumab).
15. Patients unable to comply with the protocol.
16. Active alcohol or drug abuse.
17. Patients who require therapeutic anticoagulation or antiplatelet therapy [except
treatment with Aspirin (Acetylsalicylic Acid)].
18. Patients with history of haemorrhagic or thrombotic events (including transient
ischemic attacks) in the past 12 months. Known inherited predisposition to bleeding